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A B S T R A C T
Background: Depression and chronic inflammatory medical conditions have been linked to impaired
cognitive ability. However despite frequent comorbidity, their combined association with cognitive
ability has rarely been examined.
Methods: This study examined associations between self-reported depression and chronic inflammatory
diseases and their interaction with cognitive performance in 456,748 participants of the UK Biobank,
adjusting for sociodemographic and lifestyle factors. Numbers with available data ranged from 94,899 to
453,208 depending on the cognitive test.
Results: Self-reported depression was associated with poorer performance compared to controls in
several cognitive tests (fully adjusted models, reaction time: B = 6.08, 95% CI = 5.09, 7.07; pairs matching:
incidence rate ratio = 1.02, 95% CI = 1.02, 1.03; Trail Making Test B: B = 1.37, 95% CI = 0.88, 1.87; Digit
Symbol Substitution Test (DSST): B = 0.35, 95% CI = 0.44, 0.27). Self-reported chronic inflammatory
conditions were associated with slower reaction time (B = 3.79, 95% CI = 2.81, 4.78) and lower DSST scores
(B = 0.21, 95% CI = 0.30, 0.13). No interaction effects were observed.
Discussion: In this large, population-based study we provide evidence of lower cognitive performance
in both depression and a comprehensive category of chronic inflammatory conditions. Results are
consistent with additive effects of both types of disorder on cognitive ability. Clinicians should be
aware of such effects, particularly as cognitive impairment is linked to poorer disease outcomes and
quality of life.
© 2019 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
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Depression and certain medical conditions associated with
chronic inflammation are associated with cognitive deficits [1,2],
with inflammation proposed as a potential shared mechanism
underlying these deficits [3]. In many chronic inflammatory
conditions, however, potential cognitive consequences have not
been studied, and despite frequent comorbidity of depression with
inflammatory diseases, it is unclear whether such comorbidity is
associated with worse cognitive outcomes relative to individuals
with either depression or inflammatory disease alone.
Up to two thirds of patients suffering from depression show
cognitive impairment in domains including executive function,
episodic memory, attention and processing speed [1], with these* Corresponding author.
E-mail address: laura.lyall@glasgow.ac.uk (L.M. Lyall).
http://dx.doi.org/10.1016/j.eurpsy.2019.05.007
0924-9338/© 2019 The Authors. Published by Elsevier Masson SAS. This is an open accdeficits typically persisting in euthymia [4]. Cognitive impairment
has also been observed in several chronic systemic or immune
conditions, including rheumatoid arthritis (RA) and systemic lupus
erythematosus (SLE) [2,5].
Chronic inflammation may partially explain the biology of
major depression in certain groups of patients [3]. Increased
peripheral inflammatory markers (e.g., Interleukin-6 (IL-6), C-
reactive protein (CRP), tumour necrosis factor alpha (TNFα)) are
associated with worse cognitive performance even in the absence
of disease [6], consistent with a contribution of inflammation to
the cognitive decline seen in depression [3]. Chronic inflammatory
conditions such as RA and SLE are associated with higher
prevalence of depression [7], and this comorbidity has been
associated with worse disease outcomes, e.g., in remission rates,
pain, and physical disability [8].
Studies of combined effects of depression and chronic inflamma-
toryconditions on cognitiveabilityarehoweverrare[9]. Inthecontext
of functioning and wellbeing, although effects have been small andess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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depression and chronic disease status on various health-related
outcomes. In line with the ‘amplification’ hypothesis of depression
[11], larger negative effects of depression in the presence of chronic
disease have been reported for quality of life [11] (arthritis, diabetes,
hypertension), risk of falls [12] (cardiovascular disease, diabetes,
arthritis), and activities of daily living [10] (diabetes).
Studies of combined effects of depression and chronic inflam-
matory conditions on cognitive ability are however rare. One study
found that multiple sclerosis (MS) patients with and without
depressiondidnot differontestsofverbalfluency, attentionorverbal
memory [13], while a recent systematic review found that
depression in addition to diabetes was associated with reduced
cognitive performance relative to diabetes without depression [9].
Aside from these studies, the potential for worse cognitive outcomes
in comorbid depression and inflammatory disease, and the
possibility that these types of disorders interact to have multiplica-
tive effects on cognition has remained understudied, despite
evidence of associations of cognitive decline in depression and
inflammatory conditions with reduced quality of life and increased
functional impairment [14]. We examined the association of self-
reported depression and chronic inflammatory conditions, and their
interaction, with cognitive ability in the UK Biobank cohort.
2. Methods
2.1. Participants
In 2006–2010, 502,543 adults aged 37–73 years were recruited to
the UK Biobank and completed a baseline assessment at one of 22 UK
assessment centres. Participants completed physical measures,
demographic, lifestyle, health and mood questionnaires and several
cognitive tests [15]. In 2015, participants were invited to complete
further online cognitive tests. The 456,748 participants who
completed at least one cognitive test at the baseline assessment
and/or during the follow-up internet tests, and provided data on the
sociodemographic characteristics included in fully and/or partially
adjusted models were included in this study. Ethical approval for UK
Biobank was obtained from the North West Multi-centre Research
Ethics Committee (11/NW/03820).
2.2. Cognitive tests
Novel (non-standardised) tests of reasoning, pairs matching
and reaction time were completed via a touchscreen at the baseline
assessment, and online versions of standardised cognitive tests
were completed an average of 5.82 years (SD = 0.86) later. At the
baseline assessment, numerical memory and prospective memory
were tested but are not examined here as only a subset of
participants completed the numerical memory test, and the
prospective memory test showed poor reliability [16].
2.2.1. Baseline cognitive tests
2.2.1.1. Reasoning. Participants answered up to 13 logical
reasoning questions within a 2-minute time limit: scores range
from 0 to 13. This test is referred to in UK Biobank documentation
as ‘fluid intelligence’; however as the task is not standardised and
also includes items testing crystallised intelligence, we refer to this
as ‘reasoning’ [16].
2.2.1.2. Pairs matching. Participants were presented with a grid of
12 cards and were asked to recall the positions of six matching
pairs by selecting the overturned cards onscreen. Scores reflect
visuospatial memory and consist of the number of errors before
matching all six pairs (range: 0–146).2.2.1.3. Reaction time. Participants completed a computerised
version of the card game ‘Snap’, where they were asked to press a
button as quickly as possible when two cards presented onscreen
matched. Scores consisted of the average time (milliseconds; ms)
to give a correct response: incorrect responses were rejected, and
reaction times of less than 100 ms and greater than 2000 ms were
excluded. This task measures processing speed.
2.2.2. Follow-up internet tests
2.2.2.1. Trail making test (TMT). Participants who accepted the
invitation to the follow-up assessment completed an online,
computerised version of the TMT [17]. Part A (TMT-A) involves
clicking on 25 consecutively numbered circles in ascending order.
In part B (TMT-B), participants again click on 25 circles in
ascending order, this time alternating between numbers and
letters. Scores for both parts consist of the time taken (seconds; s)
to correctly click on all circles. The task involves processing speed
and, in TMT-B, executive function [18]. For more information, see
https://biobank.ctsu.ox.ac.uk/crystal/docs/trailmaking_doc.pdf.
2.2.2.2. Digit symbol substitution test (DSST). Participants were
presented onscreen with a grid of eight symbols, each linked to a
corresponding number. Using the number pad, they filled in the
numbers corresponding to the symbols presented in boxes
onscreen. Scores consisted of the total number of boxes
correctly filled within a 2-minute time limit. This task is
thought to involve processing speed, memory, attention, and
executive function [19–21]. For more information, see https://
biobank.ctsu.ox.ac.uk/crystal/docs/symdigsub_doc.pdf.
2.3. Health variables
In a nurse-led interview during the baseline assessment,
participants were asked to report any medical conditions they
had been diagnosed with by a doctor. Illnesses were recorded by
the interviewer into a tree structure based on International
Classification of Diseases 10th Revision (ICD- 10) codes. In the
current study, a list of conditions (excluding depression) that
were reported by at least one participant and that are
considered to be typically associated with chronic inflammation
was derived and refined by three senior clinicians (JC, SS, SPL).
Participants self-reporting a condition on this list (Table A1,
Appendix A) were coded as having a ‘chronic inflammatory
condition’. For secondary analyses, the list was subdivided into
body systems based on ICD-10 chapters/sections: dermatologi-
cal, digestive/abdominal, endocrine, infections, lymphoma/
leukaemia, musculoskeletal/connective  tissue, neurological,
respiratory. See Table A1 (Appendix A) for numbers reporting
each condition and category. Conditions that are typically
chronic and/or recurrent were selected for the current study as
the medical interview did not provide sufficient details on date/
age of onset to establish if ‘acute’ conditions were present at the
time of the assessment.
For primary analyses, classification of participants with a
history of depression was based on self-report of a previous
depression diagnosis during the nurse-led interview. In additional
sensitivity analyses, we compared results when defining depres-
sion cases using criteria for probable recurrent moderate or severe
major depressive disorder (MDD), based on responses to a brief
mental health questionnaire (see [22] for details). Participants
meeting criteria for bipolar disorder or single episode depression
were excluded. In addition to the neuropsychiatric exclusions
described in Table A2 (Appendix A), participants who self-reported
depression during the medical interview were removed from the
control group.
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and on the sociodemographic covariates used in regression models
were included and coded as self-reporting depression or not, and
self-reporting one or more chronic inflammatory condition or not.
This resulted in four groups: a) neither depression nor chronic
inflammation (‘controls’); b) depression but no chronic inflamma-
tory condition (‘depression only’); c) chronic inflammatory
condition(s) but not depression (‘chronic inflammation only’);
and d) both depression and chronic inflammatory condition(s)
(‘depression plus inflammation’). Participants self-reporting cer-
tain other neuropsychiatric or neurological disorders or brain
injury were excluded (Table A2, Appendix A). Numbers of
participants in each group with available data on each cognitive
test, as well as covariates included in partially and fully adjusted
models, are summarised in Table A3 (Appendix A).
2.4. Sociodemographic and lifestyle variables
In a touchscreen questionnaire at baseline, participants were
asked to report their age, sex, ethnicity, level of education, smoking
status (‘Never’, ‘Former’, ‘Current’), and frequency of alcohol intake
(Daily (‘daily/almost daily’), Regular (‘1-2 or 3–4 times a week’),
Occasional (‘special occasions only’; ‘1-3 times a month’), or Never).
For smoking and alcohol, ‘never’ was the reference category. Based
on postcodes, Townsend deprivation scores were calculated:
negative scores reflect greater affluence.
2.5. Analysis
A series of linear regression models were conducted. Negative
binomial regression was employed for the pairs matching data, as
scores consisted of skewed, overdispersed count data with many
zero scores. In primary analyses, main effects of a) depression and
b) chronic inflammatory conditions (across both levels of the
second variable), and their interaction were examined. Main
effects were calculated by effect coding binary depression and
chronic inflammation variables as -1 (controls) and 1 (cases).
As we were interested in differences between those with
comorbid depression and chronic inflammation vs. those with oneTable 1
Descriptive statistics by self-reported depression and/or chronic inflammatory conditio
Controls
(n = 361,240)
Depression Only
(n = 19,133)
Chron
(n = 7
Age, M (SD) 56.19 (8.13) 55.03 (7.86)*† 58.54
Age at follow-up internet
tests, M (SD)
61.75 (7.73) 60.22 (7.53)*† 63.51
Female, N (%) 198,507 (54.95) 12,991 (67.90) 33,08
White, N (%) 341,795 (94.62) 18,439 (96.37) 65,67
Townsend score, M (SD) 1.44 (3.01) 0.91 (3.25)*† 0.97
Degree, N (%)
Yes 120,259 (33.29) 6,015 (31.44) 19,50
Missing data 6,834 (1.89) 169 (0.88) 1,271
Smoking status, N (%)
Never 204,448 (56.60) 9,625 (50.31) 33,82
Former 120,506 (33.36) 6,416 (33.53) 28,45
Current 35,006 (9.69) 3,033 (15.85) 8,072
Missing data 1,280 (0.35) 59 (0.31) 367 (
Alcohol intake
frequency, N (%)
Never 24,707 (6.84) 2,089 (10.92) 7,526
Occasionally 78,000 (21.59) 5,152 (26.93) 17,788
Regularly 183,452 (50.78) 8,102 (42.35) 31,58
Daily/almost daily 74,808 (20.71) 3,759 (19.65) 13,75
Missing data 273 (0.08) 31 (0.16) 68 (0
Inflammatory conditions
reported, M (SD)
– – 1.12 (
*Differs from controls. †Differs from depression plus inflammation group. zDiffers from d
variables and χ2 for categorical variables. Pairwise contrasts are Tukey’s Honestly Signitype of condition only, simple effects were also tested in a priori
contrasts. Each disease group (depression only, chronic inflamma-
tion only, and depression plus inflammation) was contrasted with
the controls, and those with depression only and chronic
inflammation only were compared with the group with both
conditions.
For each model type, base models adjusted for age, sex,
ethnicity (Caucasian vs. other) and deprivation (Townsend score).
Fully adjusted models additionally adjusted for lifestyle variables:
smoking status, frequency of alcohol intake and educational
attainment (degree vs. no degree). For primary analyses (tests of
main effects and interactions), a conservative significance thresh-
old of p < 0.001 (FDR adjusted) [23] was used for all analyses to
counter potential type-1 error associated with large numbers of
contrasts: FDR adjustment was applied across all tests reported
within each table. For descriptive statistics, a threshold of p <
0.001 (unadjusted) was applied. Robust standard errors were
employed in all models.
3. Results
3.1. Descriptive characteristics
Sociodemographic characteristics and (unadjusted) cognitive
test scores by group are displayed in Tables 1 and 2. The depression
only group were younger, and the chronic inflammation only group
were older, than the other groups. Most other characteristics
followed a relatively linear worsening pattern from controls to
depression plus inflammation: depression and/or chronic inflam-
matory conditions were associated with greater deprivation,
reduced educational attainment, decreased proportion of never-
smokers, and worse unadjusted cognitive performance.
3.2. Main effects and interactions
Main effects and interactions of depression and chronic
inflammation are summarised in Table 3. A main effect of
depression was present in partially adjusted models for all
cognitive tests, with worse performance in the group reportingn(s) groups.
ic Inflammation Only
0,715)
Depression plus Inflammation
(n = 5,660)
Test
statistic
p
 (7.68)*†z 56.87 (7.54)* 1905.94 <0.001
 (7.46)* †z 61.64 (7.46) 296.28 <0.001
9 (46.79) 3,522 (62.23) 3366.71 <0.001
0 (92.87) 5,396 (95.34) 759.09 <0.001
 (3.23)*† 0.16 (3.49)* 892.15 <0.001
3 (27.58) 1,429 (25.25)
 (1.80) 73 (1.29) 1184.15 <0.001
0 (47.84) 2,375 (41.96)
6 (40.24) 2,237 (39.52)
 (11.41) 1,019 (18.00)
0.52) 29 (0.51) 3138.17 <0.001
 (10.64) 891 (15.74)
 (25.15) 1,779 (31.43)
0 (44.66) 2,058 (36.36)
3 (19.45) 921 (16.27)
.10) 11 (0.19) 3666.75 <0.001
0.36) 1.18 (0.46) 149.77 <0.001
epression only group. Test statistics are Analysis of Variance F values for continuous
ficant Difference. BMI: body mass index; SD: standard deviation.
Table 2
Unadjusted cognitive test scores by group.
Controls (n = 361,240) Depression Only
(n = 19,133)
Chronic Inflammation
Only (n = 70,715)
Depression plus
Inflammation (n = 5,660)
Test
statistic
p
Reasoning, M (SD) (n = 154,402) 6.04 (2.15) 5.95 (2.20)† 5.79 (2.16)*z 5.66 (2.18)* 107.44 <0.001
Missing 240,092 12,812 45,703 3,739
Reaction time (ms), M (SD)
(n = 452,513)
554.80 (114.16) 565.19 (124.21)*† 573.80 (124.58)*†z 584.44 (134.66)* 634.42 <0.001
Missing 3,046 180 921 88
Pairs matching, Median (Q1, Q3)
(n = 453.208)
3 (2,6) 3 (2,6) 4 (2,6) 4 (2,6) 92.79 <0.001
Missing
TMT-A (s), M (SD) (n = 95,822) 38.88 (14.87) 39.21 (15.08) 40.36 (15.31)*z 41.19 (15.75)* 41.72 <0.001
Missing 282,639 15,506 57,985 4,796
TMT-B (s), M (SD) (n = 95,820) 65.98 (25.20) 67.61 (26.46)† 69.99 (27.33)*z 71.56 (28.09)* 102.89 <0.001
Missing 282,641 15,506 57,985 4,796
DSST, M (SD) (n = 109,003 19.89 (5.19) 19.64 (5.35)† 18.86 (5.29)*z 18.55 (5.07)* 181.86 <0.001
Missing 272,015 14,957 56,105 4,668
*Differs from controls. †Differs from depression plus inflammation group. zDiffers from depression only group. Test statistics and pairwise comparisons are Kruskal-Wallis χ2
for pairs matching, and Analysis of Variance F values and Tukey’s Honestly Significant Difference for all others. DSST = Digit Symbol Substitution Test; ms = milliseconds;
s = seconds. TMT = Trail Making Test. For N with available data for each cognitive test by group, see Table A3 (Appendix A).
Table 3
Main effects and interactions for associations of depression and chronic inflammatory conditions with cognitive performance.
Main effect of depression Main effect of inflammation Interaction
Beta (95% CI) p p FDR adj Beta (95% CI) p p FDR adj Beta (95% CI) p p FDR adj
Partially adjusted
Reasoning (n = 154,402) 0.06 (-0.09, -0.03) <0.001 <0.001 0.08 (-0.11, -0.05) <0.001 <0.001 0.01 (-0.04, 0.02) 0.470 0.584
Reaction time (n = 452,513) 6.61 (5.63, 7.59) <0.001 <0.001 4.44 (3.45, 5.42) <0.001 <0.001 0.38 (-0.60, 1.37) 0.443 0.584
Pairs matching* (n = 453,208) 1.02 (1.02, 1.03) <0.001 <0.001 1.00 (0.99, 1.00) 0.291 0.436 1.00 (0.99, 1.01) 0.713 0.755
TMT-A (s) (n = 95,822) 0.56 (0.27, 0.85) <0.001 <0.001 0.45 (0.16, 0.75) 0.002 0.004 0.11 (-0.18, 0.40) 0.456 0.584
TMT-B (s) (n = 95,820) 1.52 (1.02, 2.02) <0.001 <0.001 0.98 (0.49, 1.48) <0.001 <0.001 0.03 (-0.53, 0.46) 0.891 0.891
DSST (n = 109,003) 0.38 (-0.46, -0.30) <0.001 <0.001 0.26 (-0.34, -0.18) <0.001 <0.001 0.03 (-0.11, 0.05) 0.480 0.584
Fully adjusted
Reasoning (n = 152,507) 0.02 (-0.05, 0.002) 0.071 0.116 0.03 (-0.06, -0.005) 0.021 0.036 0.01 (-0.03, 0.02) 0.615 0.676
Reaction time (ms) (n = 442,670) 6.08 (5.09, 7.07) <0.001 <0.001 3.79 (2.81, 4.78) <0.001 <0.001 0.35 (-0.64, 1.34) 0.486 0.584
Pairs matching* (n = 446,541) 1.02 (1.02, 1.03) <0.001 <0.001 1.00 (0.99, 1.00) 0.223 0.350 1.00 (1.00, 1.01) 0.620 0.676
TMT-A (s) (n = 94,901) 0.52 (0.22, 0.81) <0.001 0.001 0.37 (0.08, 0.66) 0.014 0.024 0.11 (-0.18, 0.40) 0.472 0.584
TMT-B (s) (n = 94,899) 1.37 (0.88, 1.87) <0.001 <0.001 0.71 (0.22, 1.21) 0.005 0.009 0.06 (-0.55, 0.43) 0.812 0.835
DSST (n = 107,917) 0.35 (-0.44, -0.27) <0.001 <0.001 0.21 (-0.30, -0.13) <0.001 <0.001 0.03 (-0.11, 0.05) 0.506 0.588
* Negative binomial regression for pairs matching models – reported coefficients are incident rate ratios. Effect coding was applied to both depression (-1 = no depression; 1
= depression) and inflammation (-1 = no chronic inflammatory conditions; 1 = chronic inflammation) groups. Partially adjusted model adjusted for age, sex, ethnicity,
Townsend score. Fully adjusted model additionally adjusted for smoking status, frequency of alcohol intake and degree. CI = confidence interval; DSST = Digit Symbol
Substitution Test; FDR = False Discovery Rate; ms = milliseconds; s = seconds; TMT: Trail Making Test.
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attenuated in effect size, but all apart from reasoning and TMT-
A remained significant at the FDR adjusted p < 0.001 threshold. In
partially adjusted models, chronic inflammation was associated
with worse performance on all tests apart from pairs matching and
TMT-A. In fully adjusted models, main effects of chronic
inflammation remained only for reaction time and DSST. Inter-
actions between depression and chronic inflammation were not
significant for any cognitive test in partially or fully adjusted
models.
3.3. A priori contrasts
A priori contrasts between each disease group and controls, and
between those with depression plus inflammatory conditions vs.
all other groups are reported in Table 4. Participants reporting
depression only were slower on the reaction time and TMT-B tasks,
made more pairs matching errors, and showed reduced DSST
scores relative to controls in partially and fully adjusted models.
Participants reporting only chronic inflammatory diseases showed
deficits compared to controls in the reasoning, reaction time, TMT-
A, TMT-B and DSST tasks in partially and fully adjusted models.
Participants with both depression and inflammatory conditionswere impaired relative to controls on all cognitive tests in partially
adjusted models, and on all apart from reasoning and TMT-A in
fully adjusted models. Participants with both depression and
inflammatory conditions showed slower reaction times than those
who reported depression only (partially and fully adjusted
models). In partially and fully adjusted models, participants with
both depression and inflammation showed poorer performance on
the reaction time, pairs matching and DSST tasks compared to
those with a chronic inflammatory condition(s) only.
3.4. Sensitivity analyses
To account for the possibility that the effects of chronic
inflammation were driven by greater inflammatory disease load in
the group with both depression and inflammation (Table 1), main
effect and interaction analyses were repeated after exclusion of
participants reporting more than one chronic inflammatory
condition (Table A4, Appendix A). The significance and direction
of main effects and interactions remained unchanged.
Analyses were also repeated after coding of depression using
responses to baseline mental health questions instead of self-
reported depression diagnoses (see [22]; Table A5, Appendix A).
Main effects for depression and chronic inflammation were
Table 4
Associations between depression/inflammation status and cognitive test performance: a priori contrasts between groups.
Depression Only vs. Control Chronic Inflammation Only vs.
Control
Depression plus Inflammation vs.
Control
Depression plus Inflammation vs.
Depression Only
Depression plus Inflammation vs.
Inflammation Only
Beta (95% CI) p p FDR
adj
Beta (95% CI) p p FDR
adj
Beta (95% CI) p p FDR
adj
Beta (95% CI) p p FDR
adj
Beta (95% CI) p p FDR
adj
Partially adjusted
Reasoning (n = 154,402) 0.10 (-0.16,
-0.05)
<0.001 <0.001 0.14 (-0.17,
-0.11)
<0.001 <0.001 0.29 (-0.38,
-0.19)
<0.001 <0.001 0.18 (-0.29,
-0.07)
<0.001 0.001 0.14 (-0.24,
-0.05)
0.004 0.005
Reaction time (n = 452,513) 12.45 (10.72,
14.18)
<0.001 <0.001 8.11 (7.16, 9.07) <0.001 <0.001 22.10 (18.66,
25.54)
<0.001 <0.001 9.65 (5.83, 13.47) <0.001 <0.001 13.99 (10.45,
17.52)
<0.001 <0.001
Pairs matching*
(n = 453,208)
1.04 (1.03, 1.06) <0.001 <0.001 0.99 (0.98, 1.00) 0.007 0.009 1.04 (1.02, 1.06) <0.001 <0.001 1.00 (0.97, 1.02) 0.720 0.720 1.05 (1.03, 1.07) <0.001 <0.001
TMT-A (s) (n = 95,822) 0.90 (0.42, 1.38) <0.001 <0.001 0.69 (0.41, 0.96) <0.001 <0.001 2.03 (1.00, 3.06) <0.001 <0.001 1.13 (0, 2.26) 0.050 0.058 1.34 (0.29, 2.40) 0.013 0.016
TMT-B (s) (n = 95,820) 3.11 (2.28, 3.93) <0.001 <0.001 2.04 (1.56, 2.51) <0.001 <0.001 5.01 (3.25, 6.76) <0.001 <0.001 1.90 (-0.03, 3.82) 0.053 0.060 2.97 (1.16, 4.77) 0.001 0.002
DSST (n = 109,003) 0.70 (-0.85,
-0.55)
<0.001 <0.001 0.46 (-0.54,
-0.37)
<0.001 <0.001 1.28 (-1.57,
-0.99)
<0.001 <0.001 0.58 (-0.9,
-0.25)
<0.001 <0.001 0.82 (-1.12,
-0.52)
<0.001 <0.001
Fully adjusted
Reasoning (n = 152,507) 0.04 (-0.09,
0.02)
0.178 0.189 0.05 (-0.08,
-0.02)
<0.001 <0.001 0.11 (-0.20,
-0.02)
0.015 0.018 0.08 (-0.18,
0.03)
0.145 0.158 0.06 (-0.16,
0.03)
0.185 0.192
Reaction time (ms)
(n = 442,670)
11.45 (9.73,
13.18)
<0.001 <0.001 6.89 (5.93, 7.84) <0.001 <0.001 19.74 (16.28,
23.20)
<0.001 <0.001 8.29 (4.46, 12.12) <0.001 <0.001 12.86 (9.31,
16.41)
<0.001 <0.001
Pairs matching*
(n = 446,541)
1.04 (1.03, 1.06) <0.001 <0.001 0.99 (0.98, 1.00) 0.001 0.002 1.04 (1.02, 1.06) <0.001 <0.001 1.00 (0.97, 1.02) 0.707 0.719 1.05 (1.03, 1.07) <0.001 <0.001
TMT-A (s) (n = 94,901) 0.82 (0.34, 1.30) <0.001 0.001 0.52 (0.25, 0.80) <0.001 <0.001 1.77 (0.73, 2.80) <0.001 0.001 0.95 (-0.18, 2.08) 0.101 0.112 1.24 (0.18, 2.31) 0.021 0.025
TMT-B (s) (n = 94,899) 2.87 (2.05, 3.68) <0.001 <0.001 1.55 (1.07, 2.02) <0.001 <0.001 4.17 (2.43, 5.92) <0.001 <0.001 1.31 (-0.60, 3.22) 0.180 0.189 2.63 (0.83, 4.42) 0.004 0.005
DSST (n = 107,917) 0.65 (-0.80,
-0.50)
<0.001 <0.001 0.37 (-0.46,
-0.29)
<0.001 <0.001 1.13 (-1.42,
-0.85)
<0.001 <0.001 0.49 (-0.81,
-0.16)
0.003 0.004 0.76 (-1.06,
-0.46)
<0.001 <0.001
* Negative binomial regression for pairs matching models – reported coefficients are incident rate ratios. Partially adjusted model adjusted for age, sex, ethnicity, Townsend score. Fully adjusted model additionally adjusted for
smoking status, frequency of alcohol intake and degree. CI = confidence interval; DSST = Digit Symbol Substitution Test; FDR = False Discovery rate; ms =milliseconds; s = seconds; TMT = Trail Making Test.
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68 L.M. Lyall et al. / European Psychiatry 60 (2019) 63–70attenuated in terms of effect sizes and p values, likely due to
reduced sample size. However, as in Section 3.2., depression was
associated with more pairs matching errors and lower DSST scores
in partially and fully adjusted models. Inflammation was associat-
ed with slower reaction time and lower DSST scores in partially and
fully adjusted models. Chronic inflammation was also associated
with fewer pairs matching errors relative to controls: this is likely
linked to selection bias in the participants who reported
inflammatory conditions and also completed the mental health
questions and cognitive tests. As in primary analyses, no
interactions attained significance.
3.5. Inflammatory disease category analyses
Main effects and interactions of depression and chronic
inflammation were also examined separately for each category
of inflammatory disease (see Table A6, Appendix A for N). Mutually
exclusive categories were employed, with participants excluded
from control, depression or inflammation groups if they reported
inflammatory conditions in a second category. Fully adjusted main
effect and interaction results are displayed for dermatological;
digestive/abdominal; endocrine; infection; lymphoma/leukaemia;
musculoskeletal/connective tissue; neurological; and respiratory
conditions, respectively, in Tables A7-A14, Appendix A.
Main effects of depression were observed for musculoskeletal
models for reaction time, pairs matching and DSST. Only a small
number of main effects of depression were observed across the
remaining models (reaction time for respiratory, endocrine and
dermatological models and DSST for dermatological conditions).
This is likely linked to reduced power, as participants with
depression plus inflammatory conditions of another category were
excluded from each sub-analysis. Due to similar loss of power, null
results involving inflammation should also be interpreted with
caution. Main effects of endocrine and neurological conditions
were observed on reaction time, and main effects of neurological
conditions on digit symbol scores were observed (Tables A9, A13,
Appendix A). No interactions with depression were observed for
any category.
4. Discussion
We report associations of both depression and chronic
inflammatory medical conditions with cognitive performance in
participants of the UK Biobank, independent of sociodemographic
and lifestyle factors and education level. Depression was associat-
ed with impaired cognitive performance compared to controls in
tasks involving processing speed (reaction time, TMT-B, DSST),
visuospatial memory (pairs matching), and attentional control
(TMT-B, DSST). Chronic inflammatory conditions were associated
with slower reaction time and lower DSST scores. We did not find
evidence of interactions between depression and chronic inflam-
mation, either across all categories of inflammatory condition, or
separately by disease category, suggesting associations between
depression and cognitive abilities do not differ according to the
presence of inflammatory conditions.
The cognitive impact of many of the included medical conditions,
such as ulcerative colitis, eczema/dermatitis and gout, has rarely
been investigated. This study therefore provides important evidence
that cognitive impairments may be a feature of a wide range of
conditions associated with heightened chronic inflammation.
Associations with chronic inflammation were unchanged after
excluding participants reporting more than one inflammatory
condition, and so are unlikely to be driven by multimorbidity.
Clinicians should be aware of associations of cognitive ability with
chronic inflammation, particularly as impaired cognition is often
associated with worse disease outcomes [2,24].As heightened peripheral inflammation has been linked to
depression and was a defining feature of the chronic conditions
under study [25], findings are consistent with a role of inflamma-
tion in cognitive impairment. Several possible mechanisms may
underlie this association. Increased pro-inflammatory proteins can
cause changes in the status of neurotransmitters in the brain;
expression of trophic growth factors and rate of neurogenesis;
functioning of the hypothalamic-pituitary-adrenal (HPA) axis; and
mechanisms of learning and memory. Together, these inflamma-
tory-based mechanisms can result in a serotonin deficit and
surplus of kynurenines within the brain, mechanistically impor-
tant in both depression and cognitive impairment [3,26]. Also
relevant for cognition, Cx3cr1+ monocytes and TNFα are important
modulators of learning and memory via direct effects on neuronal
dendritic spines [27,28].
Heightened peripheral inflammation, including in depressed
patients, has been linked to reduced psychomotor speed [29],
consistent with the associations of depression and inflammation
with reaction time and DSST tasks here. Across all cognitive tests,
reaction time most reliably demonstrated associations with
depression and chronic inflammatory conditions. Power is a
potential contributor here: the sample size for the reaction time
task was higher than most others as this, along with pairs
matching, was administered throughout the baseline period
whereas only subsets of participants completed the other tests.
Information processing speed is a potential endophenotypic
marker for worse general cognitive abilities and structural brain
ageing [30]. No associations with inflammation were however
observed for pairs matching, which had similar sample size,
despite previous reports of effects of peripheral inflammation or
chronic inflammatory conditions on memory performance [2,31].
Lack of association of chronic inflammation with memory here
could be linked to poor reliability and floor effects of the pairs
matching task [16].
Overall, associations of depression with cognitive abilities
were more likely to show significance, with larger effect sizes
than for chronic inflammatory conditions. According to an
inflammatory account of cognitive impairment, this stronger
relationship with depression could reflect greater peripheral
inflammation in depression. Alternatively, other factors, for
example HPA axis dysregulation, circadian and/or sleep dis-
turbances, physical inactivity or depressive symptoms, could have
a greater influence on cognition in depression than in inflamma-
tory conditions.
The lack of interaction effects implies additive effects of
depression and chronic inflammatory conditions on cognitive
performance. Consistent with this, participants with depression
plus chronic inflammation showed worse cognitive performance
in several domains compared to those with chronic inflammatory
conditions alone, and showed slower reaction time compared to
those with depression alone. These findings have important
implications, as worse cognitive outcomes in those with both
types of disorder may lead to poorer treatment adherence and
therefore worse disease outcomes [32], as well as poorer
functional independence and quality of life [14,24]. Clinicians
should be aware that patients with chronic conditions who also
suffer from depression may require additional support due to their
potential for additional cognitive impairment.
For comparability of depression and chronic inflammation
effects, in primary analyses, equivalent self-report measures were
used for each. However, in sensitivity analyses, results were
compared with those defining recurrent MDD using mental health
questions asked at the baseline assessment (see [22]). Results were
very similar, with associations of both depression and inflamma-
tion with impaired processing speed and association of depression
with impaired memory.
L.M. Lyall et al. / European Psychiatry 60 (2019) 63–70 69A limitation of the current study is that it is not possible to
distinguish between participants who reported no medical
conditions because they do not recall any diagnoses, and those
who declined to answer this question. However, as misclassifica-
tion of individuals with existing conditions into the control group
would be expected to bias results towards the null, particularly as
individuals with cognitive impairment may be particularly likely to
fail to recall/report a condition, spurious results are unlikely to
arise from this. It is possible also that due to selection bias, patients
reporting depression/inflammatory conditions who agreed to
participate in the UK Biobank showed higher cognitive function
than would be expected in the populations with these conditions –
this could amount to a form of collider bias [33], but again, this
would be expected to bias associations towards the null.
A further limitation is that we were not able to account for
disease severity or for symptoms at the time of completing the
cognitive tests, for depression or chronic inflammatory diseases.
One possibility would have been to use participants’ self-reported
medications to account for current disease status/severity, but as
validity of self-reported medication differs widely by medication
and is likely to differ between antidepressants and medications for
chronic inflammatory conditions [34,35], this would have added
additional confounds between the two types of condition. In
addition, for many conditions there is no clear dominant form of
medication. When primary care and prescription records become
available through UK Biobank, it may be possible to more
adequately control for medication and disease severity status.
Due to the cross-sectional nature of this study, it is not possible
to infer the direction of causality. Baseline cognitive test data were
collected at the same time as self-reported diagnosis data, with
further online cognitive data collected several years later. It is
therefore unknown whether cognitive decline preceded the onset
of depressive or inflammatory disorders. Pre-existing cognitive
dysfunction may be associated with higher risk of onset of
depression or inflammatory conditions, e.g., via poorer coping
strategies, lifestyle or environmental risk. Another possibility is
that shared genetic risk factors are associated with both cognitive
impairment and risk of physical and mental health problems.
Longitudinal investigations will be of benefit in addressing the
direction of causality.
Predictions that cognitive impairments in depression and
chronic inflammatory conditions are partly driven by inflammato-
ry mechanisms can be addressed more thoroughly in future studies
which include data on inflammatory markers. For example in UK
Biobank, associations between CRP and cognition, and any
interactions with diagnoses (depression, inflammatory conditions)
could be examined. Examination of associations of genetic risk for
depression and chronic inflammatory disease (and their interac-
tion) on cognitive outcomes will also be informative.
5. Conclusions
We provide evidence of inverse associations of self-reported
depression and chronic inflammatory conditions with cognitive
performance in a large population-based cohort. Self-reported
depression was associated with slower processing speed and
poorer visuospatial memory and attentional control. Participants
reporting conditions typically associated with chronic inflam-
mation had smaller deficits (compared to depression) in
processing speed and attentional control. Interaction effects
were not observed, suggesting the relationship of depression
with cognitive function does not differ according to the presence/
absence of chronic inflammatory conditions. The group with both
depression and chronic inflammatory conditions showed the
worst cognitive performance overall, including reduced process-
ing speed and visuospatial memory compared to those withchronic inflammation only, and slower reaction time compared
to those with depression only. Clinicians should be aware of the
potential for cognitive deficits in those with depression and/or
chronic inflammatory conditions, particularly as such deficits are
likely to impact on medication adherence, functional indepen-
dence and quality of life – individuals with depression in addition
to chronic inflammatory diseases may be most at risk of such
consequences.
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